User profiles for Sherko Kümmel
 | Sherko KümmelProfessor für Medizin, Kliniken Essen-Mitte, Wissenschaftlicher Mitarbeiter Charité Berlin Verified email at kem-med.com Cited by 24470 |
[HTML][HTML] AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 update
Über viele Jahrzehnte war die komplette Ausräumung der axillären Lymphknoten im Sinne
einer Axilladissektion ein Standardverfahren in der Therapie des Mammakarzinom. Die …
einer Axilladissektion ein Standardverfahren in der Therapie des Mammakarzinom. Die …
[HTML][HTML] Event-free survival with pembrolizumab in early triple-negative breast cancer
Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a
significantly higher percentage of patients with early triple-negative breast cancer having a …
significantly higher percentage of patients with early triple-negative breast cancer having a …
[HTML][HTML] Pembrolizumab for early triple-negative breast cancer
Background Previous trials showed promising antitumor activity and an acceptable safety
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …
profile associated with pembrolizumab in patients with early triple-negative breast cancer. …
[HTML][HTML] AGO recommendations for the surgical therapy of breast cancer: update 2022
…, E Fallenberg, M Friedrich, S Kümmel… - Geburtshilfe und …, 2022 - thieme-connect.com
Die Empfehlungen der AGO Kommission Mamma zur operativen Therapie des Mammakarzinoms
wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative …
wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative …
AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022
…, E Fallenberg, M Friedrich, S Kümmel… - Senologie-Zeitschrift …, 2023 - thieme-connect.com
Die Empfehlungen der AGO-Kommission Mamma zur operativen Therapie des Mammakarzinoms
wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative …
wurden zuletzt im März 2022 aktualisiert (www.ago-online.de). Da die operative …
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to neoadjuvant
chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, …
chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive breast cancer, …
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
…, S Paepke, B Gerber, DM Zahm, S Kümmel… - The lancet …, 2014 - thelancet.com
Background Preclinical data suggest that triple-negative breast cancers are sensitive to
interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, …
interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, …
[PDF][PDF] Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and …
Purpose Modulation of immunologic interactions in cancer tissue is a promising therapeutic
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (…
strategy. To investigate the immunogenicity of human epidermal growth factor receptor 2 (…
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo …
…, M Kotliar, I Kudaba, S Kümmel… - The Lancet …, 2020 - thelancet.com
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
[HTML][HTML] A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer …
…, WD Schmitt, G von Minckwitz, J Thomalla, S Kümmel… - Annals of …, 2019 - Elsevier
Background Combining immune-checkpoint inhibitors with chemotherapy yielded an
increased response rates in patients with metastatic triple-negative breast cancer (TNBC). …
increased response rates in patients with metastatic triple-negative breast cancer (TNBC). …